<DOC>
	<DOCNO>NCT01216345</DOCNO>
	<brief_summary>The aim prospective single-centre phase II study investigate therapeutic efficacy safety cetuximab combination Gemcitabine Oxaliplatin ( GEMOX ) palliative first line treatment biliary tract cancer ( BTC ) patient .</brief_summary>
	<brief_title>Cetuximab + Gemox Biliary Tract Cancer</brief_title>
	<detailed_description>Primary Objective ( ) The primary objective study evaluate best overall response cetuximab combination gemcitabine oxaliplatin ( GEMOX ) first line treatment patient advance metastatic biliary tract cancer . Secondary Objectives The secondary objective study follow : - toxicity - secondary resection rate - progression-free survival ( PFS ) - overall survival ( OS )</detailed_description>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>histologically cytologically proven unresectable advanced metastatic biliary tract cancer ( include intrahepatic extrahepatic CC gallbladder cancer ) age ≥ 18 year ECOG performance status ≤ 2 bidimensionally measurable disease per RECIST criterion prior chemotherapy targeted therapy advance disease adequate bone marrow reserve ( neutrophil count &gt; 1500 /µL , platelet count &gt; 100,000 /µL ) adequate renal function ( serum creatinine ≤ 1.5 x upper limit normal ) adequate hepatic function ( serum bilirubin &lt; 2.5 x upper limit normal ( ULN ) serum transaminase level ≤ 5 x ULN ) write informed consent prior palliative treatment resectable disease brain metastases serious uncontrolled concurrent medical illness pregnancy nurse history malignancy exception excised cervical basal skin/squamous cell carcinoma peripheral neuropathy ( grade &gt; 1 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>